SRR10900013
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
- INTERFERON_ALPHA_RESPONSE+0.500
- HYPOXIA+0.400
- INTERFERON_GAMMA_RESPONSE+0.400
- NOTCH_SIGNALING+0.400
- ANGIOGENESIS+0.300
- CHOLESTEROL_HOMEOSTASIS+0.300
- COAGULATION+0.300
- E2F_TARGETS+0.300
- G2M_CHECKPOINT+0.300
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.100
- ESTROGEN_RESPONSE_EARLY-0.100
- ESTROGEN_RESPONSE_LATE-0.100
- KRAS_SIGNALING_DN-0.100
- KRAS_SIGNALING_UP-0.100
- OXIDATIVE_PHOSPHORYLATION-0.100
- PANCREAS_BETA_CELLS-0.100
- SPERMATOGENESIS-0.100
- ANDROGEN_RESPONSE+0.000
- APICAL_SURFACE+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934860 | — | — | 0.824 |
| 2 | 113D7756-712E-4EB4-9993-BBAF3C41AFEF | — | — | 0.815 |
| 3 | 008AE101-874B-4EB6-B811-3945E5ECCFD9 | — | — | 0.812 |
| 4 | A462D32E-3A6A-4E00-A4A7-BAF374D6009C | — | — | 0.812 |
| 5 | A9B59C46-7F32-4DD1-9649-B1788CA5E909 | — | — | 0.811 |
| 6 | A678E1E5-E02D-49A1-BB2B-C91A60E6382E | — | — | 0.809 |
| 7 | 2B311620-94F3-4B53-B66A-81AC0A32453B | — | — | 0.809 |
| 8 | C33EDB64-C7B9-49A1-AE73-1D293F8522F6 | — | — | 0.805 |
| 9 | D55CD75E-7585-47EB-936B-19BDEF7E640B | — | — | 0.803 |
| 10 | DE370889-1057-4355-AFD8-CCFCDC6CD00F | — | — | 0.803 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| HYPOXIA | 0.400 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.400 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.300 | Remibrutinib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.300 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.200 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.200 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |